SANARE spol.s.r.o.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)5 trials
• Hidradenitis suppurativa2 trials
• Psoriasis1 trial
• Vitiligo1 trial

Phase

• Phase 36 trials
• Phase 2/32 trials
• Phase 21 trial

Status

• Completed6 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Amgen2 trials
• Pfizer2 trials
• Amgen Inc.1 trial
• Avalo Therapeutics, Inc.1 trial
• Boehringer Ingelheim1 trial
• and 2 more

Running trials

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

• Active, not recruiting

  Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches

  2023-504447-14-00· Phase 2/3· Sun Pharmaceutical Industries Limited· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Amgen· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source